Latest News & Features
Americas
The most recent Illicit Trade Report states that pharmaceuticals are by far the most numerous counterfeit commodity reported, and the problem is increasing. LSIPR investigates what’s being done about it. 30 January 2015
Americas
Existing portfolios should be carefully reviewed and care must be taken in drafting new patent applications to withstand section 101 scrutiny in the US, as Judith Kim, director, and Scott Schaller, of counsel, at Sterne Kessler Goldstein & Fox, describe. 30 January 2015
Americas
Despite the headwinds facing the industry, a growing number of leading pharmaceutical companies feature on Thomson Reuters’ annual Top 100 Global Innovators list, as Bob Stembridge reports. 30 January 2015
Europe
Bringing a ‘repurposed’ drug to market requires a clear patent strategy, but clarity is unfortunately lacking in this field, say Simon Kremer and Rachel Jones of law firm Mewburn Ellis. 19 December 2014
Americas
Maximising the strength of patent protection should be an important objective of any R&D pharma company. Christine Goddard and Janis Fraser of law firm Fish & Richardson offer their six top tips for success. 19 December 2014
Big Pharma
A decision by the CJEU on a Latvian case should make it easier in the future to challenge an MA granted for a generic version of a reference product, as Trevor Cook of WilmerHale explains. 19 December 2014
Big Pharma
With its roots stretching back to oil company Shell, Crystallics underpins pharmaceutical research and development by investigating the crystalline structures of drugs and potential drug compounds. LSIPR reports. 28 November 2014
Genetics
Does the coming into force of the Nagoya Protocol represent an overdue step in the right direction towards fairness, or more red tape and unattainable expectations? Charles Brabin, a non-practising barrister, sifts through the complexities. 28 November 2014
Big Pharma
By facilitating public access to the work being done, universities face the challenge of maintaining a balance between being transparent and commercialising IP. LSIPR spoke to the head of the University of Manchester IP about walking the fine line. 28 November 2014
Americas
The Supreme Court of Canada was expected to bring the Canadian law on utility more into line with other jurisdictions, but those hopes have now received a setback, as Gunars Gaikis of Smart & Biggar/Fetherstonhaugh reports. 27 November 2014